Evin Ademoglu

Evin Ademoglu

Auto-generated profile, based on publicly available information

Evin Ademoglu

Department of Biochemistry, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2019 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
KKKucukgergin Kucukgergin
Kucukgergin Kucukgergin
EAEvin Ademoglu
Evin Ademoglu
BOBeyhan Omer
Beyhan Omer
SGSema Genc
Sema Genc
The purpose of this study was to evaluate the analytical performances of Sysmex UF-5000 and Dirui FUS-200 and to compare the results with manual microscopy and between each other. Two hundred fifty urine samples were analyzed for evaluation. Mid-stream specimens were studied sequentially using Dirui FUS-200 and Sysmex UF-5000, and also with manual microscopy within one hour. The physical and chemical components of urinalysis, and sediment results were investigated. The precision results of the FUS-200 and UF-5000 for WBCs, RBCs, and ECs were acceptable. The both analyzers demonstrated good linearity (r > 0.97), with no carry-over. The comparisons of FUS-200 and UF-5000 with manual microscopy for RBCs, WBCs, and ECs on 250 samples exhibited good agreement with little bias (R > 0.780). Only, the moderate agreements were obtained for calcium oxalate for both analyzers (R = 0.512, and 0.648, respectively). The sensitivities of the FUS-200 and UF-5000 were 75.8% and 86.8%, with specificities of 92.3% and 87.8% for WBCs, for RBCs the sensitivities were 91.1%, and 84.4% with specificities of 82.2%, and 89.6% for both analyzers. Kappa values of the UF-5000 were higher than FUS-200 for WBCs, RBCs, ECs, and calcium oxalate. The FUS-200 and UF-5000 urine analyzers, are both accurate, very precise systems and can be safely used in clinical laboratories. However, due to the technological characteristics of the UF-5000 analyzer, its positive impacts on the morphologic recognition and enumeration of RBCs and WBCs should be taken into account, particularly in university hospital laboratories with high patient volumes.

16 December 2021 in Medical Principles and Practice
Verified
Journal Article
Open access
PDF file
KKKaan Kara
Kaan Kara
SOSeda Tural Onur
Seda Tural Onur
SSSinem Nedime Sokucu
Sinem Nedime Sokucu
OKOzlem Kahya
Ozlem Kahya
COCengiz Ozdemir
Cengiz Ozdemir
EAEvin Ademoglu
Evin Ademoglu
Introduction: Galectin-3 is a multifunctional protein, the levels of which increase in the presence of diseases that progress with pulmonary fibrosis. This study investigated the role of galectin-3 levels in the staging and assessing of the severity of sarcoidosis. Methods and Subjects: Seventy-three subjects were studied; 25 were healthy individuals and 48 patients had pathologically confirmed diagnosis of sarcoidosis in which other potential causes had been ruled out. Galectin-3 levels were measured and compared in terms of such parameters as hemogram, biochemistry, age, body mass index, and smoking status. Results: The mean galectin-3 levels of the sarcoidosis patients (14.87 ± 5.57) were significantly higher than those in the healthy subjects (11.81 ± 2.67), and the mean galectin-3 levels differed significantly among different stages of the disease (p < 0.05). The serum galectin-3 level in patients with stage 2, 3, and 4 sarcoidosis was found to be higher than in patients with stage 0 and 1 sarcoidosis and the control group. In addition, serum galectin-3 levels in the sarcoidosis patients had significant positive correlations with blood urea nitrogen, alkaline phosphatase, white blood cells, red blood cell, hemoglobin, and neutrophil levels (34.9% [p < 0.05]; 40.1% [p < 0.05]; 41.2% [p < 0.01]; 43.3% [p < 0.01]; 34.7% [p < 0.05]; and 40.6% [p < 0.01], respectively) and a significant negative correlation with the platelet distribution width levels (p < 0.05). Conclusion: Serum galectin-3 levels are significantly elevated in sarcoidosis patients with parenchymal involvement at stage 2 or higher, suggesting that serum galectin-3 levels can be used to estimate disease severity in sarcoidosis.

20 December 2017 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Closed access
AOAltan Onat
Altan Onat
AKAysem Kaya
Aysem Kaya
EAEvin Ademoglu
Evin Ademoglu
Lipoproteins and the apolipoproteins (apo) that they carry are major determinants of cardiovascular diseases (CVD) as well as metabolic, renal and inflammatory chronic disorders either directly or through mediation of risk factors. The notion that elevated low-density lipoprotein cholesterol (LDL-C) and apoB levels are related to the acquisition of CVD and, high-density lipoprotein cholesterol (HDL-C) and apoA-I indicate protection against CVD has been challenged in the past decade. Advanced age, adiposity, ethnicity or impaired glucose intolerance rendered autoimmune activation in an environment of pro-inflammatory state/oxidative stress and may disrupt the linear risk association between lipoproteins. Areas covered: This review summarizes the modified risk associations of lipoproteins and apolipoprotein by an environment of chronic systemic low-grade inflammation with special emphasis on the non-linear relationship of lipoprotein(a) [Lp(a)], a biomarker of renewed interest in cardiometabolic risk. Expert commentary: It seems that autoimmune activation in an environment of pro-inflammatory state/oxidative stress not only disrupts the linear risk association between lipoproteins, but also may cause interference in immunoassays. Hence, methodological improvement in immunoassays and much further research focusing on population segments susceptible to a pro-inflammatory state is necessary for further advances in knowledge.

6 January 2022 in Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology
Verified
Journal Article
Open access
NÇNeslihan Çoban
Neslihan Çoban
AÖAybike Sena Özuynuk
Aybike Sena Özuynuk
AEAycan Fahri Erkan
Aycan Fahri Erkan
AKAyşem Kaya
Ayşem Kaya
BEBerkay Ekici
Berkay Ekici
NENihan Erginel-Ünaltuna
Nihan Erginel-Ünaltuna
Coronary artery disease (CAD) is an important public health problem worldwide. Therefore, it is important to identify the molecular mechanisms and the candidate gene polymorphisms involved in the development of CAD. In this study, we focused on 2 polymorphisms of the atherosclerosis-related genes, ESR1 and CYP19A1. Unselected 339 individuals who underwent coronary angiography were divided into 2 groups: those with normal coronary arteries (≤30% stenosis) and those with critical disease (≥50% stenosis). Individuals were genotyped for CYP19A1 rs10046 C/T and ESR1 rs2175898 A/G polymorphisms using hybridization probes in real-time PCR. In addition, Gensini and SYNTAX scores were assessed. ESR1 polymorphism was significantly associated with CAD in men (p=0.036) via G allele carriage. Multiple logistic regression analyses showed that ESR1 rare allele carriage was associated with CAD presence (Odds ratio=2.12, 95% confidence interval 1.01-4.1, p=0.025), adjusted for age, HDL-C, LDL-C and smoking status in the male group. CYP19A1 rs10046 T allele carriers had a 2.84-fold increased risk for complex CAD in multiple logistic regression analysis (p=0.016). Furthermore, the univariate analysis of variance indicated that T allele carriage of rs10046 polymorphism was associated with increased SYNTAX and Gensini scores (p<0.05). Female patients who were ESR1 G allele carriers with CAD had higher adiponectin levels (p=0.005), whereas HbA1c levels were associated with T allele of CYP19A1 in the CAD group (p=0.004) and male CAD group (p=0.018). The CYP19A1 and ESR1 polymorphisms were associated with the presence and severity of CAD. These gene polymorphisms warrant further studies for the elucidation of their contribution to CAD development.

5 October 2026 in Laboratory Medicine
Verified
Journal Article
Closed access
YYYusuf Yesil
Yusuf Yesil
AMAlpay Medetalibeyoglu
Alpay Medetalibeyoglu
EAEvin Ademoglu
Evin Ademoglu
Introduction: Routine laboratory panels are nearly universal, but the panels’ joint information is underused. We evaluated contemporaneous classification of International Statistical Classification of Diseases, Tenth Revision (ICD-10) code groups from same-encounter laboratory results. Methods: We developed 17 eXtreme Gradient Boosting (XGBoost) classifiers in 242 648 adult internal medicine encounters using age, sex, and results from 34 assays, with ICD-10 codes used only as outcomes. Stratified 10-fold cross-validation assessed discrimination, calibration, and decision curve performance. Leakage-free recalibration and fold-specific thresholds targeted 95% specificity. Using an 80-patient temporal holdout cohort, we compared the model with 3 large language models accessed through an application programming interface and findings from 1 specialist physician. Results: The mean cross-validated area under the curve (AUC) was 0.893. With identical preprocessing, the mean AUC was 0.892 for XGBoost and 0.809 for logistic regression. Recalibration changed the mean intercept and slope to −0.002 and 0.999, respectively, and the Brier score from 0.099 to 0.044. The holdout micro-averaged AUC was 0.880 vs 0.729 to 0.739 for language models; paired differences were 0.141 to 0.151 (all P < .005). Matched-specificity sensitivity differences favored the model but were imprecise. Discussion: Routine panels contain substantial information about contemporaneous ICD-10 coding, supporting prospective multicenter evaluation rather than a diagnostic claim.